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Abstract: Inﬂ  ammatory processes are increasingly recognized as important participants in the 
pathophysiology of hypertension and cardiovascular disease. Angiotensin II may be to a large 
degree responsible for triggering vascular inﬂ  ammation by inducing oxidative stress, resulting 
in up-regulation of inﬂ  ammatory mediators. Inﬂ  ammatory markers such as C-reactive protein 
are increased in the blood of patients with hypertension and predict the development of car-
diovascular disease. Moreover, C-reactive protein may be a pro-inﬂ  ammatory molecule under 
certain circumstances. C-reactive protein and high blood pressure in combination have additional 
predictive value for cardiovascular outcomes, as they contribute as independent determinants of 
cardiovascular risk. Therapeutic intervention aimed to reduce vascular inﬂ  ammation in hyper-
tensive patients has been proposed. Recent lines of evidence suggest that lifestyle modiﬁ  cation 
and pharmacological approaches may reduce blood pressure and inﬂ  ammation in patients with 
hypertension. Antagonism of the renin-angiotensin system with the selective angiotensin recep-
tor blockers may improve cardiovascular outcome beyond blood pressure control, by reducing 
vascular inﬂ  ammation and remodeling.
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Introduction
Low grade inﬂ  ammation localized in vascular tissue is increasingly recognized as an 
important contributor to the pathophysiology of hypertension (De Ciuceis et al 2005), 
to the initiation and progression of atherosclerosis and the development of cardiovas-
cular disease (CVD) (Savoia and Schiffrin 2006, 2007). Patients with CVD present 
increased expression and plasma concentrations of inﬂ  ammatory markers and mediators 
(Blake and Ridker 2001; Sesso et al 2003). Among them, C-reactive protein (CRP) has 
been demonstrated as an independent risk factor for the development of hypertension 
(Blake et al 2003; Thorand et al 2003), and has been associated with increased risk 
of diabetes (Barzilay et al 2004) and CVD. Numerous epidemiological studies have 
shown that plasma levels of high-sensitivity CRP (hsCRP) are a powerful predictor of 
ischemic cardiovascular events in patients with stable or unstable angina. They appears 
to correlate with softer plaques that are more prone to rupture, and may even predict 
cardiovascular events among apparently healthy subjects (Ridker et al 1997, 1998). 
Furthermore, hsCRP levels have been shown to correlate with systolic blood pressure 
(BP), pulse pressure, and incident hypertension (Chae et al 2001). Thus CRP and high 
BP in combination have additional predictive value for cardiovascular outcomes, as 
they contribute as independent determinants of cardiovascular risk.
The activation of the renin-angiotensin system (RAS) is primarily involved in the 
pathophysiology of hypertension and the development of CVD (Schiffrin and Touyz 
2004). In addition to its effect on BP, angiotensin II is also a proinﬂ  ammatory mediator 
(Kranzhofer et al 1999; Pastore et al 1999). Antagonism of the RAS may improve 
cardiovascular outcomes beyond BP control, by reducing vascular inﬂ  ammation and 
remodeling.Vascular Health and Risk Management 2007:3(6) 976
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In this review we discuss the role of CRP as marker and/or 
mediator of low-grade inﬂ  ammation in the vasculature of 
hypertensive patients and the potential advantages of antihy-
pertensive medication that may attenuate the inﬂ  ammatory 
mechanisms associated with hypertension.
RAS, inﬂ  ammation, 
and hypertension
The activated components of the RAS play a key role in the 
pathophysiology of hypertension (Schiffrin and Touyz 2004). 
Angiotensin II, one of the ﬁ  nal products of the RAS, induces 
vascular remodeling and injury by several mechanisms. These 
include vasoconstriction, cell growth, generation of reactive 
oxygen species (ROS), and inﬂ  ammation. Angiotensin II can 
induce inﬂ  ammation within the vascular wall (Figure 1) and 
consequently trigger deposition of extracellular matrix, and 
hypertrophy and/or hyperplasia of vascular smooth muscle 
cells (VSMCs) (Touyz and Schiffrin 2000) by modulating 
cytokine release (Schieffer et al 2000) and pro-inﬂ  ammatory 
transcription factors such as NF-κB (Hernandez-Presa et al 
1997), which in turn regulate adhesion molecule (VCAM-1 
and ICAM-1) expression (Pueyo et al 2000).
Angiotensin II, aldosterone, as well as endothelin-1, 
can modulate basal superoxide production by activation 
of reduced nicotinamide adenine dinucleotide phosphate 
[NAD(P)H] oxidase and expression of its subunits (Lassegue 
and Clepmpus 2003). NAD(P)H oxidase is the major 
source of ROS in the vascular wall, and is expressed in 
endothelial cells, VSMCs, ﬁ  broblasts, and monocytes/macro-
phages (Griendling et al 2000; Touyz et al 2002) (Figure 1). 
ROS act as signaling molecules, but also in part by impair-
ing endothelium-dependent vascular relaxation by reducing 
the bioavailability of nitric oxide (NO) (Rajagopalan et al 
1996; Jung et al 2003). Vascular contractile responses are 
accordingly enhanced, associated with structural changes in 
the wall of small arteries and increased peripheral resistance 
(Touyz et al 2003). Increased ROS production induced 
by angiotensin II is involved in the mechanisms leading 
to vascular remodeling, through VSMC proliferation and 
hypertrophy and collagen deposition (Touyz and Schiffrin 
2001). ROS promote vascular inﬂ  ammation (Touyz and 
Schiffrin 2004) and exert effects on the development 
and progression of atherosclerosis (Kalinina et al 2002). 
Angiotensin II-induced ROS production increases ICAM-1 
expression, macrophage inﬁ  ltration, macrophage/monocyte 
chemoattractant protein-1 (MCP-1) production, and vascular 
hypertrophy independently of BP elevation (Liu et al 2003). 
Macrophages which inﬁ  ltrate the adventitia or the media of 
blood vessels may generate oxidative stress by NAD(P)H 
oxidase, also in response to elevated BP (Schiffrin and Touyz 
2003a). Mice deﬁ  cient in monocytes/macrophages present 
less oxidative stress and less induction of inﬂ  ammatory 
molecule upregulation by angiotensin II in the vasculature, 
and develop less endothelial dysfunction and vascular remod-
eling (De Ciuceis et al 2005). This suggests a central role for 
macrophages and pro-inﬂ  ammatory mediators in angiotensin 
II-induced vascular injury.
Angiotensin II is also involved in atherosclerotic lesion 
progression and plaque instability by stimulating the activa-
tion of MMPs (matrix metalloproteinases), which can digest 
the ﬁ  brous cap and thereby participate in the triggering of 
plaque rupture (Galis et al 1994). In addition, angiotensin II 
stimulates the production of plasminogen activator inhibitor-I 
(PAI-1) (Vaughan et al 1995), which may contribute not 
only to the prothrombotic state but also to plaque rupture in 
atherosclerotic lesions.
C-reactive protein as biomarker 
and mediator of inﬂ  ammation
CRP is a pentameric protein produced mainly by hepatocytes 
under the control of interleukin-6 as part of the non-speciﬁ  c 
acute-phase response to tissue damage, infection, inﬂ  amma-
tion and malignant neoplasia (Pepys and Hirschﬁ  eld 2003). 
Recent ﬁ  ndings have documented that CRP is also produced 
by vascular smooth muscle cells and endothelial cells, and 
in human atheroma (Yasojima et al 2001; Venugopal et al 
2005). Increased levels of serum CRP, particularly sensed by 
high sensitivity assay, are generally regarded as a humoral 
sign of inﬂ  ammation, and may identify subjects at moder-
ate or high risk of cardiovascular disease. hsCRP has been 
related to insulin resistance, systolic BP, pulse pressure and 
hypertension (Chae et al 2001; Engstrom et al 2002). hsCRP 
correlates with plasma levels of von Willebrand factor 
(vWF), tissue plasminogen activator, and cellular ﬁ  bronectin, 
which are markers of endothelial dysfunction (Yudkin et al 
1999). Numerous epidemiological studies have shown that 
plasma hsCRP level is a powerful predictor of ischemic car-
diovascular events in patients with stable or unstable angina, 
appears to be positively associated with softer plaques that are 
more prone to rupture (Liuzzo et al 1994), may even predict 
cardiovascular events among apparently healthy subjects 
(Ridker et al 1997, 1998), and may be useful in targeting 
medium-risk patients who could beneﬁ  t from aggressive 
cardiovascular preventative therapy.
Vascular inﬂ  ammation of large arteries exerts its effects 
in part by impairing artery elasticity and increasing vascular Vascular Health and Risk Management 2007:3(6) 977
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stiffness, in the presence or absence of hypertension. A 
correlation between CRP and measures of arterial wave reﬂ  ec-
tion and stiffness in asymptomatic subjects was recently dem-
onstrated (Kullo et al 2005). CRP levels were also associated 
with the future development of hypertension independently 
of baseline BP (Sesso et al 2003; Chrysohoou et al 2004), 
although this issue has been recently challenged (Niskanen 
et al 2004). In the Women’s Health Study which included 
over 15,000 women, after adjustment for the effects of other 
cardiovascular risk factors, high levels of CRP appeared to 
be predictive of cardiovascular events either in the absence 
or presence of high BP. In the latter case the risk was three-
fold higher to that in the low CRP/low BP group (Blake et al 
2003). However, after adjustment for confounding factors, 
elevated CRP levels appear not to lead to elevated BP (Smith 
et al 2005). Thus, both CRP and BP seem to be independent 
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Figure 1 Scheme of angiotensin II-induced inﬂ  ammation and vascular damage.
Abbreviations: Ang II, angiotensin II; EC, endothelial cell; ECM, extracellular matrix; ET-1, endothelin-1; ICAM, intercellular adhesion molecule; NAD(P)H oxidase, 
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determinants of cardiovascular risk, and, in combination, each 
parameter may have additional predictive value (Chae et al 
2001; Engstrom et al 2002; Blake et al 2003).
CRP may be more than an inﬂ  ammatory biomarker of 
increased cardiovascular risk, as deposits of CRP have been 
demonstrated by immunohistochemical staining in athero-
sclerotic plaques (Figure 2), where it co-localizes with the 
terminal complement complex and appears to be involved in 
foam cell formation (Torzewski et al 2000). CRP promotes 
monocyte chemotaxis (Zwaka 2001) and facilitates low-
density lipoprotein uptake by macrophages in vitro (Zwaka 
et al 2001). In endothelial cells, CRP facilitated the release 
of PAI-1 (Devaraj et al 2003) and endothelin-1 (Verma 
et al 2002), and increased the expression of cell adhesion 
molecules (Pasceri et al 2000), reduced NO bioavailability 
(Venugopal et al 2002), and NO-mediated dilation in the 
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Figure 2 Scheme of C-reactive protein-induced inﬂ  ammation.
Abbreviations: Ang II, angiotensin II;  AT1R, angiotensin type 1 receptor; BP, blood pressure; CRP, C-reactive protein; ET-1, endothelin-1; ICAM, intercellular adhesion 
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vasculature. In particular, CRP inhibited endothelium-
dependent NO-mediated dilatation of coronary arterioles by 
inducing the generation of superoxide by NAD(P)H oxidase 
via p38 kinase activation (Qamirani et al 2005). On the other 
hand, it has been reported that CRP per se does not activate 
endothelial cells. The latter has been attributed to contamina-
tion of CRP preparations with azide and lipopolysaccharide, 
which could be responsible for the cell activation (Taylor 
et al 2005). In VSMCs, CRP increased angiotensin type 1 
receptor number and ROS formation (Wang et al 2003), as 
well as activation of the stress-activated protein kinases p38 
and c-jun N-terminal kinase (JNK) (Hattori et al 2003). It was 
recently reported that CRP caused a sustained increase in 
systolic BP in mice, related to an augmented pressor response 
to angiotensin II that is associated with a NO-sensitive down-
regulation of vascular angiotensin type 2 receptor expression 
(Vongpatanasin et al 2007).
Along with the evidence that CRP is a marker and a 
modulator of inﬂ  ammation, it has also been shown that CRP 
may possess anti-inﬂ  ammatory actions. CRP inhibited neu-
trophil activation and adhesion (Heuertz and Webster 1997; 
Zouki et al 1997) and blocked platelet aggregation in vitro 
(Fiedel and Gewurz 1976; Vigo 1985; Miyazawa et al 1988). 
Accordingly, it has been proposed that distinct isoforms of 
CRP are formed during inﬂ  ammation. CRP could dissoci-
ate into individual subunits that undergo conformational 
changes. The resulting monomeric CRP isoforms, express 
several neoepitopes and display properties distinct from those 
of native CRP (Potempa et al 1987; Zouki et al 2001; Khreiss 
et al 2002). Monomeric CRP is less soluble than pentameric 
CRP, it tends to aggregate, and induces a pro-inﬂ  ammatory 
phenotype in human endothelial cells (Khreiss et al 2004a). 
Monomeric CRP antigens were detected in inﬂ  ammed tissues 
and in the wall of normal human blood vessels, and displayed 
potent pro-thrombotic activity under low levels of shear. In 
contrast, native CRP inhibited platetelet activation and pre-
vented neutrophil–endothelial-cell and neutrophil–platelet 
adhesion. Hence monomeric CRP rather than native CRP 
may be involved in the precipitation of acute coronary syn-
drome (Khreiss et al 2004b).
Thus, CRP may be a pro-inﬂ  ammatory molecule under 
certain circumstances, as well as a marker to consider in 
medium-risk cardiovascular patients.
Reducing vascular inﬂ  ammation 
via antagonism of the RAS
Arterial BP control is critical to reduce the burden of 
cardiovascular morbidity and mortality. Indeed, arterial 
hypertension contributes to increase the latter in combina-
tion with other cardiovascular risk factors (such as obesity, 
diabetes and dyslipidemia). JNC-VII and WHO-ISH and 
other national and international guidelines have suggested 
different non-pharmacological and pharmacological 
approaches to reduce BP in hypertensive patients (Chobanian 
et al 2003; Whitworth and Chalmers 2004). Since hyperten-
sion is a pro-inﬂ  ammatory condition, non-pharmacological 
(weight loss, exercise and Mediterranean-style diet) and 
pharmacological therapeutic intervention to control BP 
have also been proposed to reduce vascular inﬂ  ammation in 
patients with hypertension, in order to achieve a reduction of 
cardiovascular events and improved outcomes in randomized 
clinical trials.
Several therapeutic approaches have been shown to reduce 
CRP in patients at high cardiovascular risk. Exercise training, 
together with weight loss, reduced hsCRP levels signiﬁ  cantly, 
although not in proportion to weight reduction (Obisesan et al 
2004). CRP decrease was observed in the middle weight-
reduction quartile, suggesting that there may be an optimal 
link between exercise and weight loss with respect to the 
inﬂ  ammatory status (Obisesan et al 2004). Patients consum-
ing a Mediterranean-style diet had a signiﬁ  cant reduction in 
serum concentrations of hsCRP, IL-6, IL-7, and IL-18, as 
well as in insulin resistance (Esposito et al 2004).
In patients with high LDL-cholesterol levels, those 
with low hsCRP have better clinical outcomes than 
those with higher levels (Nissen et al 2005; Ridker et al 
2005). Fenoﬁ  brate lowered hsCRP levels in patients with 
hypertriglyceridemia or combined hyperlipidemia (Koh 
et al 2005a). Statin-induced reduction of atherosclerosis 
progression was signiﬁ  cantly related to greater reduction 
of hsCRP levels. Simvastatin or atorvastatin induced a 
reduction of CRP in coronary patients with hyperlipid-
emia (Strandberg et al 1999). In patients with diabetes 
and hypercholesterolemia, simvastatin combined with the 
angiotensin converting enzyme (ACE) inhibitor ramipril 
signiﬁ  cantly reduced CRP levels more than monotherapy 
(Koh et al 2005b).
In hypertensive patients in the presence or absence 
of diabetes, BP control with ACE inhibitors, angiotensin 
receptor blockers (ARBs), and calcium channel blockers 
was associated with a reduction in the circulating levels of 
inﬂ  ammatory mediators (Gasic et al 1999; Sardo et al 2004; 
Agabiti-Rosei et al 2005a, b). Several lines of evidence 
suggest that the improvement in systemic and vascular 
inflammatory status observed in patients treated with 
antihypertensive medications might involve BP-independent Vascular Health and Risk Management 2007:3(6) 980
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actions, which have been attributed in part to direct inhibition 
of pro-inﬂ  ammatory effects of angiotensin II (Koh et al 2003; 
Schiffrin and Touyz 2003b). However, not all studies have 
demonstrated anti-inﬂ  ammatory effects of agents that inter-
rupt RAS. There is evidence that drugs that selectively block 
angiotensin II receptors or ACE may have superior anti-
inﬂ  ammatory properties than other antihypertensive agents. 
In subjects with uncomplicated hypertension, ACE inhibitors 
but not ARBs decreased plasma levels of adhesion molecules 
(VCAM-1, ICAM-1, E-selectin) (Jilma et al 2002). In older 
patients, ARBs reduced circulating levels of VCAM-1 but not 
of E-selectin (Rajagopalan et al 2002). In diabetic nephropa-
thy, ARBs decreased plasma adhesion molecules (Andersen 
et al 2000). In type 2 diabetic patients, ARBs diminished 
VCAM-1, whereas ACE inhibitors reduced ICAM-1 (Guba 
et al 2000). We recently reported that antihypertensive treat-
ment with an ARB ameliorated inﬂ  ammatory processes and 
markedly reduced circulating pro-inﬂ  ammatory mediators 
in diabetic hypertensive patients, independently by BP or 
glycemic control (Touyz et al 2007). Furthermore, CRP-
induced up-regulation of the angiotensin type 1 receptor was 
attenuated by losartan (Wang et al 2003). In another study 
in hypertensive patients, although MCP-1 and PAI-1 were 
variably reduced, losartan, irbesartan, or candesartan did 
not signiﬁ  cantly reduce serum CRP (Koh et al 2004). Also, 
whereas three small randomized clinical trials in patients with 
hypertension and cardiovascular disease showed a signiﬁ  cant 
CRP-lowering effect by an ARB (Yasunari et al 2004; Fliser 
et al 2004; Schieffer et al 2004), in another study in hyper-
tensive and diabetic patients no lowering of CRP could be 
detected (Agabiti-Rosei et al 2005a).
Recently, the Val-MARC (Valsartan-Managing blood 
pressure Aggressively and evaluating Reductions in hsCRP) 
study, addressed the issue of whether BP reduction per 
se lowers CRP levels, or whether selective antagonism 
of angiotensin type 1 receptors may have independent 
effects to reduce CRP levels (Ridker et al 2006). The 
study included 1668 patients with stage 2 hypertension 
randomly allocated to either the ARB valsartan alone 
(160–320 mg/day) or to valsartan/hydrochlorothiazide 
(HCTZ, 160–320 mg/12.5 mg/day) for a period of 6 weeks. 
At the end of the treatment, valsartan alone slightly but sig-
niﬁ  cantly reduced hsCRP levels, effect that was maintained 
over an extended follow-up period. In contrast the combi-
nation therapy did not reduce CRP levels. The difference 
between valsartan and valsartan/HCTZ was present in all 
subgroups evaluated despite the fact that BP reduction was 
greater in the combined therapy group. Minimal evidence 
of correlation between change in BP and change in hsCRP 
was observed. Interestingly, CRP reduction associated 
with valsartan treatment was observed not only in the total 
cohort but also among the subjects taking statins, a class of 
agents that has been shown to signiﬁ  cantly reduce hsCRP 
levels (Strandberg et al 1999; Albert et al 2001; Koh et al 
2005b; Ridker et al 2005). Thus, these data support the 
hypothesis that ARBs may have anti-inﬂ  ammatory effects 
independently of the degree of BP reduction. However, the 
implication of the very small change in CRP found with 
valsartan vs valsartan plus HCTZ remains unclear, as does 
the therapeutic importance of this difference, since in the 
clinic, most patients who receive an ARB also receive a 
thiazide diuretic. Nevertheless, these ﬁ  ndings have recently 
been conﬁ  rmed by a study performed in a large multiethnic 
cohort of patients receiving pharmacologic treatment for 
hypertension in which the use of ACE inhibitors and ARBs 
as monotherapy was associated with lower CRP levels 
(Palmas et al 2007).
Observational studies in patients with cardiovascular 
disease have also suggested that ARBs and ACE inhibitors 
lower serum CRP. In patients with ischemic heart disease 
undergoing heart catheterization, lower serum levels of CRP 
were observed when the patients were treated with an ARB 
(Takeda et al 2003). After coronary artery bypass surgery, 
patients who had received ACE inhibitors had lower levels of 
IL-6, the main modulator of CRP release by the liver (Brull 
et al 2002). Moreover, ACE inhibitor use was associated with 
lower CRP levels in patients with heart failure (Joynt et al 
2004). In the Val-Heft study, patients with congestive heart 
failure randomized to treatment with the ARB valsartan had 
lower hsCRP levels, whereas placebo-treated subjects did 
not (Arnand et al 2005).
Conclusion
Hypertension may be considered a disease associated with 
low-grade inﬂ  ammation that contributes to cardiovascu-
lar disease. Non pharmacological and pharmacological 
approaches to control high BP may decrease vascular 
inﬂ  ammation independently of BP reduction in patients with 
hypertension, resulting in reduced cardiovascular events in 
randomized clinical trials. Among other antihypertensive 
agents, ARBs have shown more potent anti-inﬂ  ammatory 
properties unrelated to BP-lowering effect of this class of 
drugs, but more probably the result of a direct antagonism 
of the pro-inﬂ  ammatory effects induced by angiotensin II. 
Thus, although reducing BP is the primary goal in order to 
decrease cardiovascular events in hypertensive patients, Vascular Health and Risk Management 2007:3(6) 981
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reduction of low-grade inﬂ  ammation in hypertension may 
be an interesting and important target in order to reduce 
the cardiovascular morbidity and mortality associated with 
hypertension.
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